Prognostic Relevance of the Modified Glasgow Prognostic Score in Patients Treated with Enfortumab Vedotin + Pembrolizumab for Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the GUARDIANS Cohort

Background and Objective: Enfortumab vedotin plus pembrolizumab (EV+P) is the first-line standard of care for metastatic urothelial carcinoma (mUC), but outcomes remain heterogeneous despite high response rates. The modified Glasgow Prognostic Score (mGPS), derived from C-reactive protein and albumin, is a prognostic tool across solid tumors but has not been evaluated in patients receiving EV+P. We aimed to determine whether baseline mGPS is independently associated with overall survival (OS) and progression-free survival (PFS) in this population. Methods: We retrospectively analyzed 310 patients treated with first-line EV+P across 19 German centers in the GUARDIANS registry, stratified by baseline mGPS (0: CRP ≤10 mg/L; 1: CRP >10 mg/L, albumin ≥35 g/L; 2: CRP >10 mg/L, albumin <35 g/L). OS and PFS were estimated by Kaplan–Meier methods and compared by log-rank test. Multivariable Cox regression, adjusted for age, ECOG status, and liver metastases, assessed independent prognostic value and discrimination (Harrell’s C-index), which was compared with that of the Bellmunt risk score. Key Findings and Limitations: mGPS was independently associated with both OS and PFS. mGPS 1 and mGPS 2 (vs. mGPS 0) carried hazard ratios of 2.26 (95% CI 1.19–4.29) and 3.11 (95% CI 1.46–6.63) for OS, and 1.63 (95% CI 1.09–2.45) and 2.36 (95% CI 1.43–3.90) for PFS (all p≤0.018; C-index 0.71 and 0.65, respectively). mGPS discriminated similarly to the established Bellmunt risk score (standalone C-index 0.65 vs. 0.66 for OS and 0.62 vs. 0.60 for PFS). ECOG status was also prognostic; liver metastases were not. Limitations include the retrospective design and immature OS follow-up. Conclusions and Clinical Implications: mGPS is a simple, independent, readily available prognostic marker for first-line EV+P that may complement established risk factors for stratification and merits prospective validation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11669920/v1
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prognostic Relevance of the Modified Glasgow Prognostic Score in Patients Treated with Enfortumab Vedotin + Pembrolizumab for Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the GUARDIANS Cohort

Viktor Grünwald, Nina Holzwarth, Nadja Strewinsky, Kiriaki Hiller et al.
3 links
Research Square
Inflammatory Biomarkers in Disease Prognosis
preprint

Prognostic Relevance of the Modified Glasgow Prognostic Score in Patients Treated with Enfortumab Vedotin + Pembrolizumab for Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the GUARDIANS Cohort

Viktor Grünwald, Nina Holzwarth, Nadja Strewinsky, Kiriaki Hiller, Thomas Büttner, Eva Erne, Katrin Schlack, Philipp Schmucker, Can Aydoğdu, Frederik Wessels, Severin Rodler, Christopher Darr, Jozefina Casuscelli, Florian Siegel, Pia Paffenholz, Subhajit Mandal, Ludwig O. Pachmayr, Susan Foller, Niklas Klümper, Johannes Zeyda, Schnabel Marco, Muammar Dib, Louis Rhode, Stefanie Zschäbitz, Friedemann Zengerling, Emily Rinderknecht, Anna-Lisa Volk, Martin Hennig
preprint en

Abstract

Background and Objective: Enfortumab vedotin plus pembrolizumab (EV+P) is the first-line standard of care for metastatic urothelial carcinoma (mUC), but outcomes remain heterogeneous despite high response rates. The modified Glasgow Prognostic Score (mGPS), derived from C-reactive protein and albumin, is a prognostic tool across solid tumors but has not been evaluated in patients receiving EV+P. We aimed to determine whether baseline mGPS is independently associated with overall survival (OS) and progression-free survival (PFS) in this population. Methods: We retrospectively analyzed 310 patients treated with first-line EV+P across 19 German centers in the GUARDIANS registry, stratified by baseline mGPS (0: CRP ≤10 mg/L; 1: CRP >10 mg/L, albumin ≥35 g/L; 2: CRP >10 mg/L, albumin <35 g/L). OS and PFS were estimated by Kaplan–Meier methods and compared by log-rank test. Multivariable Cox regression, adjusted for age, ECOG status, and liver metastases, assessed independent prognostic value and discrimination (Harrell’s C-index), which was compared with that of the Bellmunt risk score. Key Findings and Limitations: mGPS was independently associated with both OS and PFS. mGPS 1 and mGPS 2 (vs. mGPS 0) carried hazard ratios of 2.26 (95% CI 1.19–4.29) and 3.11 (95% CI 1.46–6.63) for OS, and 1.63 (95% CI 1.09–2.45) and 2.36 (95% CI 1.43–3.90) for PFS (all p≤0.018; C-index 0.71 and 0.65, respectively). mGPS discriminated similarly to the established Bellmunt risk score (standalone C-index 0.65 vs. 0.66 for OS and 0.62 vs. 0.60 for PFS). ECOG status was also prognostic; liver metastases were not. Limitations include the retrospective design and immature OS follow-up. Conclusions and Clinical Implications: mGPS is a simple, independent, readily available prognostic marker for first-line EV+P that may complement established risk factors for stratification and merits prospective validation.

Research Square
University of Cologne (DE), Heidelberg University (DE), Universitätsklinikum Gießen und Marburg (DE), University Hospital Bonn (DE), University Medical Center Freiburg (DE), University Hospital Heidelberg (DE), LMU Klinikum (DE), Düsseldorf University Hospital (DE), Universitätsklinikum Tübingen (DE), University Hospital Münster (DE), Vivantes Klinikum (DE), University Hospital Schleswig-Holstein (DE), Essen University Hospital (DE), Universitätsklinikum Würzburg (DE), Jena University Hospital (DE), University Hospital Magdeburg (DE), University Hospital Cologne (DE), University Hospital Ulm (DE), University Medical Centre Mannheim (DE), University of Regensburg (DE), Technical University of Munich (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon